Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EK 193

Next Previous
X
Search
Drug Profile

EK 193

Alternative Names: CD19-CD3 bispecific antibody injection - Beijing Luzhu Biotechnology; EK 193 antibody injection - Beijing Luzhu Biotechnology; EK193 - Beijing Luzhu Biotechnology; K 1932; K1932 Antibody Injection

Latest Information Update: 03 Apr 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Beijing Luzhu Biotechnology
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Lymphoma

Most Recent Events

  • 03 Apr 2023 Beijing Luzhu Biotechnology files an IND application with the US FDA for Lymphoma Prior to March 2023 (Beijing Luzhu Biotechnology pipeline, March 2023)
  • 13 Mar 2023 Preclinical trials in Lymphoma in China (Parenteral) (Beijing Luzhu Biotechnology pipeline, March 2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top